title: Donor cell leukemia developing after hematopoietic stem cell transplantation for multiple myeloma.
abstract: The development of secondary leukemia in donor cells after allogeneic stem cell transplantation is a rare event. We describe the occurrence of acute myeloid leukemia in donor cells 4 years after a stem cell transplantation for multiple myeloma. The multiple myeloma was relapsing at the time of the onset of acute myeloid leukemia. Secondary leukemia in donor cells after transplantation for multiple myeloma has not yet been reported.
authors.affiliation: Service d'Hématologie, Centre de Génétique, Secteur Hématologie, Cliniques universitaires Saint-Luc, 1200 Bruxelles.
authors.forename: V
authors.initials: V
authors.lastname: Havelange
authors.forename: H
authors.initials: H
authors.lastname: Antoine-Poirel
authors.forename: P
authors.initials: P
authors.lastname: Saussoy
authors.forename: E
authors.initials: E
authors.lastname: Van Den Neste
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D019520:Living Donors; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D015255:Idarubicin